Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07

Spark Therapeutics (ONCE) PT Lowered to $77 at Barclays

Barclays lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $77.00 (from $85.00) while maintaining a Overweight rating.

BMO Capital Downgrades Spark Therapeutics (ONCE) to Market Perform

BMO Capital downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to Market Perform with a price target of $60.00 (from $98.00).

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $77.61 yesterday.

Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey

SunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.

Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More

Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen

Cowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.

Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More

Spark Therapeutics (ONCE) PT Lowered to $64 at RBC Capital

RBC Capital lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $75.00) while maintaining a Sector Perform rating.

Analyst Kennen MacKay said the view today's SPK-8011 update suggestive of efficacy and safety below investor expectations and expect the stock to be choppy into ASH data detailing today's update.

Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection

Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.

Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More

BioMarin Pharma (BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (ONCE)

BioMarin Pharma (NASDAQ: BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (NASDAQ: ONCE)